RT Journal Article
SR Electronic
T1 Saliva viral load is a dynamic unifying correlate of COVID-19 severity and mortality
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.01.04.21249236
DO 10.1101/2021.01.04.21249236
A1 Silva, Julio
A1 Lucas, Carolina
A1 Sundaram, Maria
A1 Israelow, Benjamin
A1 Wong, Patrick
A1 Klein, Jon
A1 Tokuyama, Maria
A1 Lu, Peiwen
A1 Venkataraman, Arvind
A1 Liu, Feimei
A1 Mao, Tianyang
A1 Oh, Ji Eun
A1 Park, Annsea
A1 Casanovas-Massana, Arnau
A1 Vogels, Chantal B. F.
A1 Muenker, M. Catherine
A1 Zell, Joseph
A1 Fournier, John B.
A1 Campbell, Melissa
A1 Chiorazzi, Michael
A1 Fuentes, Edwin Ruiz
A1 ,
A1 Grubaugh, Nathan D.
A1 Farhadian, Shelli
A1 Cruz, Charles Dela
A1 Ko, Albert I.
A1 Schulz, Wade L.
A1 Ring, Aaron
A1 Ma, Shuangge
A1 Omer, Saad
A1 Wyllie, Anne L
A1 Iwasaki, Akiko
YR 2021
UL http://medrxiv.org/content/early/2021/01/06/2021.01.04.21249236.abstract
AB While several clinical and immunological parameters correlate with disease severity and mortality in SARS-CoV-2 infection, work remains in identifying unifying correlates of coronavirus disease 2019 (COVID-19) that can be used to guide clinical practice. Here, we examine saliva and nasopharyngeal (NP) viral load over time and correlate them with patient demographics, and cellular and immune profiling. We found that saliva viral load was significantly higher in those with COVID-19 risk factors; that it correlated with increasing levels of disease severity and showed a superior ability over nasopharyngeal viral load as a predictor of mortality over time (AUC=0.90). A comprehensive analysis of immune factors and cell subsets revealed strong predictors of high and low saliva viral load, which were associated with increased disease severity or better overall outcomes, respectively. Saliva viral load was positively associated with many known COVID-19 inflammatory markers such as IL-6, IL-18, IL-10, and CXCL10, as well as type 1 immune response cytokines. Higher saliva viral loads strongly correlated with the progressive depletion of platelets, lymphocytes, and effector T cell subsets including circulating follicular CD4 T cells (cTfh). Anti-spike (S) and anti-receptor binding domain (RBD) IgG levels were negatively correlated with saliva viral load showing a strong temporal association that could help distinguish severity and mortality in COVID-19. Finally, patients with fatal COVID-19 exhibited higher viral loads, which correlated with the depletion of cTfh cells, and lower production of anti-RBD and anti-S IgG levels. Together these results demonstrated that viral load – as measured by saliva but not nasopharyngeal — is a dynamic unifying correlate of disease presentation, severity, and mortality over time.Competing Interest StatementAkiko Iwasaki served as a consultant for Spring Discovery and Adaptive BiotechnologiesFunding StatementThis work was supported by the NIH Medical Scientist Training Program Training Grant T32GM136651; the Womens Health Research at Yale Pilot Project Program; Fast Grant from Emergent Ventures at the Mercatus Center, Mathers Foundation, and the Ludwig Family Foundation; the Department of Internal Medicine at the Yale School of Medicine; Yale School of Public Health and the Beatrice Kleinberg Neuwirth Fund. IMPACT received support from the Yale COVID-19 Research Resource Fund. A.I. is an Investigator of the Howard Hughes Medical Institute. C.L. is a Pew Latin American Fellow. P.Y is supported by Gruber Foundation and the NSF. B.I. is supported by NIAID 2T32AI007517-16. C.B.F.V. is supported by NWO Rubicon 019.181EN.004.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by Yale Human Research Protection Program Institutional Review Boards (FWA00002571, protocol ID 2000027690). Informed consent was obtained from all enrolled patients and healthcare workers.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll the background information on HCWs, clinical information for patients, and raw data used in this study are included in Extended Table 4. Additionally, all of the raw .fcs files for the flow cytometry analysis are available